P

Prolific Machines

Develops cost-efficient cultured meat production

Head of Hardware Engineering

Full-Time
$220k - $270k/yr+ Equity package
Expert
Bachelor's, Master's, PhD
Emeryville, CA, USA
In PersonOn-site in Emeryville; occasional remote work is flexible.
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A BS, MS, or PhD in Mechanical, Electrical, Optical, Systems, or Biomedical Engineering, or a related field; equivalent experience is considered.
  • At least 10 years of relevant industry experience, including at least 3 years leading a multidisciplinary hardware engineering team or department as a people manager, such as a senior manager or director.
  • Demonstrated experience taking at least one hardware product from an R&D prototype through production and field deployment, including concrete examples of what you would do differently next time.
  • A track record of setting multi-year technical or functional strategy and translating it into execution plans, budgets, and resourcing.
  • Hands-on experience bringing hardware into a regulated environment, such as GMP, FDA design controls, or equivalent, and leading products through electrical safety certification such as UL, CE, or similar.
  • Deep technical expertise in at least one core discipline—mechanical, electrical, or optical—and sufficient breadth to make sound architecture decisions across the others.
  • A strong track record of mentoring engineers and growing individual contributors into leads.
  • Experience managing external development partners, contract manufacturers, or suppliers against defined scopes and milestones.
  • Strong written and verbal communication, including explaining complex technical tradeoffs in scope, quality, time, and human resources to executives, partners, and non-engineers.
Responsibilities
  • Translate company strategy into a multi-year hardware strategy and roadmap, and turn it into concrete functional plans, milestones, and success measures.
  • Partner with the CTO to define the company's technical roadmap, engineering standards, and decision-making frameworks.
  • Contribute to company business planning as the hardware function's representative, including budgets, headcount, capital equipment, and partner program commitments.
  • Make most operational and technical decisions for the hardware function independently, escalating when strategic alignment is needed.
  • Build partnerships with peer leaders in bioprocess engineering, biology, software, data, and business development so hardware plans integrate with company-wide priorities.
  • Represent the company externally with partners, suppliers, and the broader engineering community, and bring outside expertise and industry connections into the company.
  • Align the hardware team behind company decisions and agreed outcomes, including when they differ from your own recommendation.
  • Conserve and strengthen the hardware team's culture of collaboration, candor, and craftsmanship as the team grows.
  • Lead, mentor, and develop a multidisciplinary team, elevating engineers and growing senior individual contributors into technical and people leads.
  • Coach the team in balancing speed and rigor, including when to prototype quickly, when to slow down, and how to make those decisions confidently.
  • Own the structure and operations of the hardware function, including team design, roles, resourcing, planning, design reviews, and retrospectives.
  • Identify hardware team capability gaps, write the hiring plan, and hire people who strengthen the culture.
  • Communicate tradeoffs in scope, quality, time, and people effectively up and down the organization.
  • Define subsystem boundaries and interfaces, requirements flow-down, and modular hardware designs that enable rapid scaling, independent testing, and component reuse without over-engineering early.
  • Solve difficult, unprecedented technical problems in scaling light delivery to industrial bioprocessing and develop durable solutions.
  • Oversee the full development lifecycle, from technical scoping and concept through prototyping, verification and validation, and transfer to production.
  • Lead the transition from R&D prototypes to reliable, serviceable, manufacturable products through design for manufacturing, design for service, and design controls.
  • Drive make-versus-buy and insource-versus-outsource decisions, and manage external development partners and contract manufacturers against clear scopes and milestones.
  • Support business development with technical scoping and realistic estimates for partner programs.
  • Define and execute the path to GMP readiness for hardware used in partner manufacturing environments.
  • Lead electrical safety and regulatory certification efforts with test labs and consultants.
  • Establish appropriately scaled quality practices for each stage, including documentation, change control, verification records, and supplier qualification.
  • Work with hardware operations to ensure the team's designs can be built, deployed, and supported at scale.
  • Own the roadmap for the next-generation illuminator platform, including oversight of external development partners.
  • Establish an operating rhythm for planning, design reviews, and delivery.
  • Set standards for documentation, communication, and other good engineering practices.
Desired Qualifications
  • Strong systems engineering judgment, including the ability to decide whether a dedicated systems engineer is needed and to lead that work until then; a track record of architecting modular, scalable hardware platforms is a strong signal.
  • Familiarity with life science hardware, such as bioprocessing equipment, lab instrumentation, or medical devices.
  • Experience with optical systems, LED or laser illumination, or thermal management of high-power electronics.
  • Experience with equipment used in pharmaceutical manufacturing, including qualification (IQ/OQ/PQ) and GAMP-style validation.
  • Experience scaling a fleet of deployed systems from a handful of units to dozens or more.
  • Experience at an early-stage company, ideally through a period of rapid team growth.
  • Working knowledge of firmware, embedded systems, and connected devices sufficient to partner effectively with firmware and software leads.

About the company

temp

Company Size

51-200

Company Stage

Series B

Total Funding

$147M

Headquarters

Emeryville, California

Founded

2020

Get referred to Prolific Machines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2026 Gates Foundation grant funds affordable monoclonal antibodies for low-income countries.
  • 2026 site lists services for biotechs, CDMOs, and licensing, broadening revenue paths.
  • May 2025 FDA program status improves credibility with regulators and pharma partners.

What critics are saying

  • The company pivoted from cultured meat toward biopharma, confusing employer branding and hiring.
  • No 2026 customer revenues are public, so commercialization still depends on partner conversions.
  • If biomanufacturing deals stall, Prolific risks becoming a funded platform without durable demand.

What makes Prolific Machines unique

  • 2026 website says Prolific integrates optogenetic cell lines, illumination, AI optimization.
  • May 2025 FDA Emerging Technology Program entry validates its industrial biomanufacturing platform.
  • June 2024 Series B1 drew Fonterra, Breakthrough Energy Ventures, and In-Q-Tel.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Hybrid Work Options
  • Company Equity
  • Mental Health Support
  • Paid Vacation
  • Meal Benefits
  • Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

3%
Vialynx Inc
Oct 14th, 2026
Prolific Machines announces new investment led by Nant Capital and Atoms & Bits as well as a strategic NantWorks collaboration, and Board appointments.

Prolific Machines announces new investment led by Nant Capital and Atoms & Bits as well as a strategic NantWorks collaboration, and Board appointments. Science · OCT 14, 2026 PR Newswire Prolific Machines announced a new investment led by Atoms & Bits and Nant Capital to scale its optogenetics-enabled biomanufacturing platform. The company... * Prolific Machines announced a new investment led by Atoms & Bits and Nant Capital to scale its optogenetics-enabled biomanufacturing platform. * The company also entered a strategic collaboration with NantWorks to apply its platform across biologics programs within NantWorks' health and life sciences portfolio. * Patrick Soon-Shiong, M.D. and James Stewart have joined Prolific Machines' Board of Directors. EMERYVILLE, Calif, Oct. 14, 2026 /PRNewswire/ - Prolific Machines, the biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced the initial closing of its $50M Series B2 financing led by Atoms & Bits, a growth-stage fund, and Nant Capital, the investment organization which is part of a portfolio of private and public companies in health and life sciences founded by Patrick Soon-Shiong, M.D. This brings the company's total funding to over $100 million. Prolific Machines will use the new capital to scale its optogenetics platform for biomanufacturing, expanding programs with several top-20 pharma companies and multiple biotechs at its San Francisco Bay Area campus and across its CDMO network. The funding will support team growth, further technology development and scale-up across novel biologics, biosimilars and viral vector programs. It will also fund early work toward tissue and organ fabrication. Prolific Machines and NantWorks also announced a strategic collaboration to apply Prolific's platform across biologic programs within NantWorks' portfolio of health and life sciences companies. "For the last seven years the Prolific Machines team has been creating the field of Optogenetic Biomanufacturing, allowing any process inside of any cell to be controlled with light. Our goal is to provide the lowest cost and highest precision infrastructure to control biology. We have demonstrated that it works, can be scaled, and that people want it. Our biggest issue now is having too much demand and this funding round changes that. We will be rapidly scaling the business over the next 12 months," said Deniz Kent, Ph.D., CEO and Co-Founder of Prolific Machines. As part of the financing, James Stewart, founder of Level One Fund and Atoms & Bits, and Patrick Soon-Shiong, M.D., founder of NantWorks, have joined Prolific Machines' Board of Directors. Existing investors, including Breakthrough Energy Ventures, Mayfield, SOSV, and Fonterra's venture arm, also participated in the round. "Prolific Machines is the most exciting advancement I have seen in biopharma manufacturing in decades. Deniz and his team have built the control system that has long been missing from making medicines in living cells. I look forward to NantWorks, its affiliate companies and Prolific working together on multiple fronts," said Patrick Soon-Shiong, M.D., founder of NantWorks. "Prolific's optogenetic platform brings precise, programmable control to cells, with major potential across biopharma and beyond. Its early traction already shows strong commercial promise," commented James Stewart, General Partner of Atoms & Bits. About Prolific Machines Prolific is a biotechnology-driven company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control. Its next-generation integrated platform combines light-inducible cell lines, plug-and-play illumination systems, and AI-driven process optimization to enable dynamic control of protein expression in standard bioreactors. Prolific partners with biotech and pharmaceutical companies and CDMOs worldwide to advance programs from development toward scalable, cost-efficient manufacturing. To learn more, visit prolific-machines.com About Atoms & Bits Atoms & Bits is a growth-stage venture capital firm backing companies at the intersection of the digital and physical worlds. Founded by the teams behind Level One Fund and Primal Capital, the firm partners with founders leveraging advances in AI, software and computation to build transformative products and infrastructure in the physical world. Learn more at https://atomsandbits.xyz. About NantWorks NantWorks, LLC applies new innovative approaches and new technologies to solving global problems. NantWorks is focusing on three pillars: health & life sciences; energy & renewables; and connectivity & communications. Founded by Dr. Patrick Soon-Shiong, scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane, the core mission for NantWorks is convergence: to develop and deliver a diverse range of technologies that accelerate innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. Media Contacts SOURCE Prolific Machines Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.

Fierce Pharma
Oct 14th, 2026
NantWorks' Soon-Shiong puts chips behind manufacturing disruptors in new rounds for Prolific Machines, Multiply Labs

With demand for advanced manufacturing solutions mounting across the industry, the moment is ripe to capitalize on investor interest and build out toward a potential production paradigm shift.&nbsp | With demand for advanced manufacturing solutions mounting across the industry, the moment is ripe to capitalize on investor interest and build out toward a potential production paradigm shift.

Business Wire
Feb 13th, 2025
Prolific Machines Announces the Appointment of Former Forge Biologics Executive, Christina Perry, as CFO Setting the Stage for Optogenetics Leader's Biopharmaceutical Commercial Ramp Up

Christina Perry, MSA, CPA, former Chief Financial Officer (CFO) of Forge Biologics, recently acquired by Ajinomoto Co., has been appointed as CFO of Prolific Machines to support the company's meteoric growth as it works towards building a resilient, sustainable business.

Business Wire
Aug 16th, 2024
Prolific Machines Receives Grant to Develop a Platform to Produce Affordable Monoclonal Antibodies to Prevent Infectious Disease in Low- and Middle-Income Countries

Prolific Machines receives Bill & Melinda Gates Foundation grant to leverage optogenetics expertise to develop more affordable monoclonal antibodies.

Webrazzi
Jun 7th, 2024
Prolific Machines raises $55M for light-based protein

Biotechnology startup Prolific Machines, which uses a photomolecular platform to create new proteins at low costs, has raised $55 million in a Series B1 round led by Fonterra's VC arm, The Ki Tua Fund. Other investors include Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures, and In-Q-Tel (IQT). The funding will be used to commercialize their platform through industry partnerships.